Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ionis Pharmaceuticals Inc...

    NASDAQ: IONS · Real-Time Price · USD
    43.39
    3.45 (8.64%)
    At close: Jul 02, 2025, 2:46 PM
    8.64%
    Bid 43.38
    Market Cap 6.91B
    Revenue (ttm) 717.44M
    Net Income (ttm) -458.03M
    EPS (ttm) -2.99
    PE Ratio (ttm) -14.51
    Forward PE -12.43
    Analyst Buy
    Ask 43.46
    Volume 2,808,097
    Avg. Volume (20D) 1,732,278
    Open 39.97
    Previous Close 39.94
    Day's Range 39.86 - 43.54
    52-Week Range 23.95 - 52.34
    Beta 0.18

    About IONS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IONS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IONS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Ionis Pharmaceuticals Inc. is scheduled to release its earnings on Jul 31, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 hour ago
    Ionis Pharmaceuticals shares are trading higher on... Unlock content with Pro Subscription
    7 months ago
    -7.76%
    Shares of pharmaceutical and healthcare stocks are trading lower. The sector has been under pressure after president-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.
    news image

    3 days ago · seekingalpha.com

    Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight

    Ionis is transitioning from a licensing model to a commercial-stage biotech, investing heavily in its own drug launches and development pipeline. Upcoming catalysts include donidalorsen's FDA decision...

    news image

    1 week ago · businesswire.com

    Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BII...

    news image

    2 weeks ago · businesswire.com

    Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective J...

    news image

    3 weeks ago · businesswire.com

    First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluat...

    news image

    1 month ago · zacks.com

    Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

    Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

    news image

    1 month ago · zacks.com

    Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

    Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.

    news image

    1 month ago · businesswire.com

    Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia ...

    news image

    1 month ago · businesswire.com

    Ionis to host 2025 virtual Annual Meeting of Stockholders

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corpora...

    news image

    2 months ago · zacks.com

    Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

    IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

    news image

    2 months ago · seekingalpha.com

    Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

    Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP ...

    Add to Watchlist